More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine

por Verheijen, S., van Luin, M., Brüggemann, R.J., de Mast, Q., Hassing, R.J., Burger, D.M.
Publicado 2021

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy

por Wijting, IEA, Rutsaert, SL, Rokx, C, Burger, DM, Verbon, A, van Kampen, JJA, Boucher, CAB, Rijnders, BJA, Vandekerckhove, L
Publicado 2018

Relating protease inhibitor resistance at time of virological failure with drug exposure

por Van Luin, M, Bannister, WP, Paredes, R, Phillips, AN, Bruun, J, Van Lunzen, J, Kirk, O, d'Arminio Monforte, A, Cozzi-Lepri, A, Burger, DM
Publicado 2010

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

por Overbeek, J.K., Heine, R. ter, Verheul, H.M.W., Chatelut, E., Rudek, M.A., Gurney, H., Plummer, R., Gilbert, D.C., Buclin, T., Burger, D.M., Bloemendal, H.J., van Erp, N.P.
Publicado 2023

Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals

por Brüggemann, R.J., Moes, D.J.A.R., van Rhee, K.P., van 't Veer, N.E., Koch, B.C.P., van Rossum, M., Windsant - van den Tweel, A. Vermeulen, Reijers, M.H.E., van Kimmenade, R.R.J., Rahamat-Langedoen, J.C., Rettig, T.C.D., van Raalte, R., van Paassen, J., Polderman, F.N., van der Linden, P.D., Frenzel, T., de Mast, Q., Burger, D.M., Schouten, J., van de Veerdonk, F.L., Pickkers, P., ter Heine, R.
Publicado 2021